Home > > Vendors > EndoGlow

EndoGlow: Redefining the Surgical Landscape with Enhanced Visual Capabilities

Follow EndoGlow on :

Dr. Paula Doyle, Chief Medical Officer

The invention of minimally invasive surgery (MIS) has undoubtedly redefined the global surgical landscape. In fact, the market is estimated to reach USD 32.7 billion in 2025 from USD 20.1 billion in 2019, at a CAGR of 8.5 percent during the forecast period. The growth is rather justifiable considering the increasing number of MIS producers across the globe and the long list of advantages it offers over traditional open surgeries, which include—but are not limited to—small incisions, less pain, low risk of infection, short hospital stays, quick recovery time, less scarring, and reduced blood loss. It also helps surgeons reduce risks associated with conventional open surgeries by allowing them to do more delicate and complex work with accuracy.

However, much like any other type of medical surgery, MIS is far from perfect. Dr. Paula Jaye Doyle, the Chief Medical Officer of EndoGlow, explains this out of the personal experience. “I’ve had several frustrating experiences during robotic surgeries. I was oftentimes encountered with scar tissues and anatomical distortion, which could evolve as health issues for my patients.”

Although the advanced visual technologies in MIS equipment allowed Dr. Doyle to see the anatomy’s surface topography, they lacked the potential to unlock subsurface visibility. Besides, robotic surgeries lacked haptic feedback, preventing Dr. Doyle from feeling the tissue during the procedure. Upon discussing these concerns with her colleagues during a research meeting, Dr. Doyle realized that several surgeons worldwide face similar hardships. Identifying the global need for more visual information to enhance decision making during robotic surgeries, Dr. Doyle decided to design and develop a robust fluorescent technology solution. By leveraging her real-world robotic surgical experience and spending several years researching different chemistries, materials, and formulations, the research team came up with a one-of-its-kind Tissue Reveal Technology (TRT). This spurred the conception of EndoGlow, a medical device company that provides enhanced visualization capabilities to surgeons during minimally invasive surgeries by using MIS equipment’s Near Infrared (NIR) capability. “We manufacture fluorescent medical devices that fluoresce under NIR, anticipating the need for the ability to see in different wavelengths outside the visible spectrum in the future surgical landscape,” says Dr. Doyle.

With the ability to highlight surgical planes and expose anomalies under the tissue surface, TRT enables surgical teams to see through tissues and gain more visual information, helping them eliminate surgical complications. The solution is designed to transilluminate tissues, providing surgeons with information such as tissue depth, tissue quality, anatomical borders, and sub-surface pathology.

“Our cutting-edge fluorescence-based technology is designed by surgeons for surgeons,” adds Dr. Doyle. What gives TRT an edge over fluorescent dyes is its capability to embed fluorescence into conventional surgical tools, ensuring zero disruption to the surgical flow. It serves as a reliable solution for pelvic surgery, including gynecology, urology, and colorectal as by providing fluorescence without the use of batteries or external power, iodine, and Indocyanine green. In addition to its application in real-world operating rooms, TRT helps shorten surgical trainees’ learning curve.

To make this state-of-the-art technology readily available to the surgical community, EndoGlow has designed and developed two robust products, GreenEgg™ and SoGreen™. Several surgeons across the U.S. have highlighted their capability to eliminate risks of scars associated with bladder dissection in pelvic surgery, reduce the time for surgical procedures, and increase their confidence during their pilot study. “We are waiting for the FDA approval for our products, which are anticipated to reach the hands of surgeons in the first quarter of 2021,” mentions Dr. Doyle.

With such a powerful value proposition powered by the right blend of medical and engineering expertise, EndoGlow envisions expanding its product roadmap going forward. The company is now focusing on building comprehensive marketing strategies to get their devices in as many surgeons’ hands as possible. As an aggressive startup, EndoGlow is constantly expanding its strategic partnerships to accelerate their marketing, sales and research activities.

“We envision revolutionizing the way surgeries are being conducted by providing the necessary tools for surgeons to help them deliver truly modern healthcare to patients at a competitive price,” concludes Dr. Doyle.

Share this Article:

Company
EndoGlow

Headquarters
Rochester, NY

Management
Dr. Paula Doyle, Chief Medical Officer

Description
EndoGlow makes fluorescent surgical instruments used to enhance visualization during minimally invasive surgeries. The company’s solutions are backed by their one-of-its-kind Tissue Reveal Technology (TRT) that provides more visual information to surgeons to help them enhance their decision making during laparoscopic and robotic surgeries. With the ability to highlight surgical planes and expose anomalies under the tissue surface, TRT enables surgical teams to see through tissues and gain more visual information, helping them eliminate surgical complications. The solution is designed to transilluminate tissues, providing surgeons with information such as tissue depth, tissue quality, anatomical borders, and sub-surface pathology